Crescent Biopharma Announces Grants of Inducement Awards

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) granted inducement stock options covering an aggregate 16,950 ordinary shares to two non-executive employees under its 2025 Employment Inducement Incentive Award Plan.

The options, approved May 28, 2026, have a 10-year term, a $21.47 exercise price, and time-based vesting over four years.

Argus Jun 1 session

-4.50% close to close 1.3x rel. volume Open Argus

Details

News Market Reaction – CBIO

On Jun 1, the first trading day after this news, CBIO closed 4.50% below the previous close.

Data tracked by StockTitan Argus for the Jun 1 session.

Key Figures

Inducement option shares: 16,950 shares Employees receiving grants: 2 employees Exercise price: $21.47 per share +5 more

Inducement option shares

16,950 shares

Aggregate options for two non-executive employees

Employees receiving grants

2 employees

Non-executive hires receiving inducement awards

Exercise price

$21.47 per share

Equal to Nasdaq closing price on May 28, 2026

Option term

10 years

Duration of inducement stock options

Initial vesting portion

1/4 of shares

Vests on first anniversary of employee start date

Ongoing vesting rate

1/48 of shares monthly

Monthly vesting after first anniversary, subject to service

Inducement plan year

2025 plan

Crescent Biopharma 2025 Employment Inducement Incentive Award Plan

Current share price

$21.47

Matches option exercise price and 52-week low

Historical Context

5 past events · Latest: May 21

5 events

1. May 21

   ASCO trial update

   24h Move

   +2.5%

   Announced Trial-in-Progress ASCEND study poster for CR-001 at ASCO 2026.

2. May 12

   Inducement awards

   24h Move

   +6.2%

   Granted stock options to five non-executive employees under 2025 inducement plan.

3. May 06

   Investor conferences

   24h Move

   -0.1%

   Planned management presentations at three healthcare and oncology investor conferences.

4. Apr 29

   Earnings & pipeline

   24h Move

   +6.8%

   Reported Q1 2026 results, strong cash of $189.2M and ongoing oncology trial progress.

5. Apr 24

   Inducement awards

   24h Move

   +1.4%

   Announced inducement option grants to two employees totaling 12,525 shares.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

equity inducement awards, nasdaq listing rule 5635(c)(4), exercise price, option agreement

4 terms

equity inducement awards financial

"shares to two non-executive employees as equity inducement awards under"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

nasdaq listing rule 5635(c)(4) regulatory

"with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"a 10-year term and an exercise price equal to $21.47, the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

option agreement financial

"terms of the Inducement Plan and the terms and conditions of an option agreement"

An option agreement is a contract that gives one party the right, but not the obligation, to buy or sell a specific asset (like company shares or property) at a pre-agreed price within a set time period. Think of it like a reservation or ticket that holds a purchase at today’s terms for later — it matters to investors because it can create potential future value or liability, change ownership stakes, and affect share dilution and company control.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 16,950 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on May 28, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $21.47, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on May 28, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma 

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X. 

Contacts

Investors

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media

Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock options did Crescent Biopharma (Nasdaq: CBIO) grant on May 28, 2026?

Crescent Biopharma granted options to buy an aggregate 16,950 ordinary shares to two non-executive employees. According to Crescent Biopharma, these equity inducement awards were approved under the 2025 Employment Inducement Incentive Award Plan and were material to each employee’s acceptance of employment.

What is the exercise price and term of Crescent Biopharma (CBIO) 2026 inducement options?

The inducement options have a 10-year term and an exercise price of $21.47 per share. According to Crescent Biopharma, this price equals the May 28, 2026 Nasdaq closing price of its ordinary shares, aligning the grants with market value at approval.

How do the Crescent Biopharma (CBIO) inducement stock options vest for new employees?

The options vest 25% on the first anniversary of each employee’s start date, then monthly thereafter. According to Crescent Biopharma, one-forty-eighth of the shares vests monthly after year one, subject to continuous service through each applicable vesting date.

Why did Crescent Biopharma use Nasdaq Listing Rule 5635(c)(4) for CBIO inducement awards?

Crescent Biopharma used Nasdaq Listing Rule 5635(c)(4) to grant equity awards as a material inducement to employment. According to Crescent Biopharma, these options were important to each employee’s acceptance and were made under the company’s 2025 Employment Inducement Incentive Award Plan.

How many shares are covered by Crescent Biopharma’s May 2026 inducement option grants?

The May 2026 inducement grants cover options to purchase an aggregate 16,950 ordinary shares for two employees. According to Crescent Biopharma, these options are issued under the 2025 Employment Inducement Incentive Award Plan and are governed by individual option agreements.